AZD 2836

Drug Profile

AZD 2836

Alternative Names: A-831; AZD2836

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Arrow Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 26 Sep 2008 Arrow Therapeutics terminates a phase I/II trial in Hepatitis C in UK and New Zealand
  • 31 Aug 2007 Phase-I/II clinical trials in Hepatitis C in United Kingdom (PO)
  • 31 Aug 2007 Phase-I/II clinical trials in Hepatitis C in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top